간행물

Journal of Gynecologic Oncology (JGO) update

  • : 대한부인종양학회(구 대한부인종양·콜포스코피학회)
  • : 의약학분야  >  산부인과학
  • : KCI등재
  • : SCI,SCOPUS
  • : 연속간행물
  • : 격월
  • : 2005-0380
  • :
  • : 대한부인종양.콜포스코피학회잡지(~2004)→부인종양(2005~)→Journal of Gynecologic Oncolgy (JGO)(2008~)

수록정보
수록범위 : 1권1호(1990)~30권1호(2019) |수록논문 수 : 1,432
Journal of Gynecologic Oncology (JGO)
30권1호(2019년 01월) 수록논문
최근 권호 논문
| | | |

다운로드

(기관인증 필요)

초록보기

Objective: There is no definitive guideline for the significance and cut-off value of squamous-cell carcinoma antigen (SCC-Ag) in cervical cancer. Thus, we analyzed the significance and optimal cut-off value of SCC-Ag for predicting tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix.
Methods: From January 2010 to October 2016, we enrolled 304 cervical cancer patients with squamous-cell carcinoma staging International Federation of Gynecology and Obstetrics (FIGO) Ib-IVa and treated with definitive chemoradiotherapy (CRT) followed by intra-cavitary radiotherapy (ICR). The cut-off value of SCC-Ag level for tumor recurrence was calculated using the receiver operating characteristic (ROC) curve. The recurrence-free survival (RFS) and overall survival (OS) were assessed using Kaplan-Meier method to estimate the significance of SCC-Ag level.
Results: The optimal cut-off value of SCC-Ag level for predicting tumor recurrence was calculated and set at 4.0 ng/mL in the ROC curve. After a median follow-up period of 36.5 months, the 3-year RFS (56.6% vs. 80.2%, p<0.001) and OS (72.1% vs. 86.8%, p=0.005) were significantly lower in SCC-Ag ≥4 ng/mL arm than in <4 ng/mL arm. The 3-year locoregional recurrence (17.6% vs. 7.0%, p=0.012), distant metastasis (20.4% vs. 6.9%, p=0.002), and para-aortic recurrence (9.4% vs. 2.1%, p=0.012) rates were significantly higher in SCC-Ag≥4 ng/mL arm than in SCC-Ag <4 ng/mL arm.
Conclusion: Pre-treatment SCC-Ag level higher than 4 ng/mL may be a useful predictor of tumor recurrence in patients with squamous-cell carcinoma of uterine cervix treated with definitive CRT and ICR.

KCI등재 SCI SCOPUS

2Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?

저자 : Jihye Kim , Youjean Chang , Tae-joong Kim , Jeong-won Lee , Byoung-gie Kim , Duk-soo Bae , Chel Hun Choi

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-13 (13 pages)

다운로드

(기관인증 필요)

초록보기

Objective: Elderly age is one of the poor prognostic factors in epithelial ovarian cancer (EOC), but the optimal age cut-off is not known. The present study sought to identify the ideal age cutoff that represents a negative prognostic factor in EOC, considering the geriatric assessment.
Methods: Hazard ratios (HRs) with p-values were calculated using all possible age cutoffs with stage, histology, grade, optimality and comorbidities as covariates in multivariate Cox regression model. The trends of p-value and HR by age cutoff were further evaluated in a subgroup of histology and in The Cancer Genome Atlas (TCGA) dataset. In addition, propensity score-matching analysis using the identified age cutoff was performed.
Results: An age of 66 years was shown to be the most significant cutoff for defining old age with independent prognostic power (HR=1.45; 95% confidence interval=1.04-2.03; p=0.027). This result was also observed with the analyses of serous histology subgroup and with the analysis of a TCGA dataset with serous EOC. In survival analysis, patients aged ≥66 years had significantly worse overall survival compared with younger individuals (56 months vs. 87 months; p=0.006), even following propensity score matching (57 vs. 78 months; p=0.038).
Conclusion: An age of 66 years is the best cutoff to define elderly age in serous EOC patients considering the geriatric assessment, and this information can be used in the administration of individualized therapies in elderly EOC patients.

KCI등재 SCI SCOPUS

3Serum calcium is a novel parameter to assess metabolic syndrome in endometrial carcinoma

저자 : Yanying Lin , Jingyi Zhou , Linlin Cao , Qi Xu , Juan Hao , Lijun Zhao , Jianliu Wang

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-9 (9 pages)

다운로드

(기관인증 필요)

초록보기

Objectives: To investigate the distribution of serum calcium and the relationship between serum calcium and serum metabolic parameters in endometrial carcinoma (EC) patients.
Methods: Retrospective assessment of patients diagnosed with endometrial cancer from Peking University People's Hospital from 2004 to 2009. Clinical characteristics as well as pretreatment serum calcium, albumin, fasting plasma glucose (FPG), serum triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC) value were extracted from patient records. Serum calcium was corrected for albumin. Unpaired t test and analysis of covariance were used to compare serum calcium among categorical variables. Simple correlation analyses and partial correlation analyses were used to assess the associations between serum calcium and continuous variables.
Results: Two-hundred twenty patients were included in this study. After adjusting for confounders, postmenopausal patients had higher total serum calcium (p=0.002) and albumin-corrected serum calcium (p=0.012) than premenopausal patients, endometrioid endometrial carcinoma (EEC) patients had higher total serum calcium than non-endometrioid endometrial carcinoma (NEEC) patients (p=0.037). Significant positive correlations were found between total serum calcium and FPG (p=0.017), TG (p=0.043), HDL (p=0.042), LDL (p<0.001), and TC (p<0.001) after adjusting for multiple variables, and the corrected serum calcium showed no significant correlation with metabolic parameters.
Conclusion: Total serum calcium might be a more sensitive parameter for metabolic syndrome in endometrioid endometrial cancer patients than lipids.

KCI등재 SCI SCOPUS

4The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification

저자 : Jun Guan , Liying Xie , Xuezhen Luo , Bingyi Yang , Hongwei Zhang , Qin Zhu , Xiaojun Chen

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-14 (14 pages)

다운로드

(기관인증 필요)

초록보기

Objectives: Although patients with grade I and II endometrioid endometrial adenocarcinoma (EEA) are considered with good prognosis, among them 15%-25% died in 5 years. It is still unknown whether integrating estrogen receptor (ER) and progesterone receptor (PR) into clinical risk stratification can help select high-risk patients with grade I-II EEA. This study was to investigate the prognostic value of ER and PR double negativity (ER/PR loss) in grade I-II EEA, and the association between ER/PR loss and The Cancer Genome Atlas (TCGA) classification.
Methods: ER and PR were assessed by immunohistochemistry on hysterectomy specimens of 903 patients with grade I-II EEA. ER and PR negativity were determined when <1% tumor nuclei were stained. Gene expression data were obtained from the TCGA research network.
Results: Compared with ER or PR positive patients (n=868), patients with ER/PR loss (n=35) had deeper myometrial infiltration (p=0.012), severer FIGO stage (p=0.004), and higher rate of pelvic lymph node metastasis (p=0.020). In univariate analysis, ER/PR loss correlated with a shorter progression-free survival (PFS; hazard ratio [HR]=5.25; 95% confidence interval [CI]=2.21-12.52) and overall survival (OS; HR=7.59; 95% CI=2.55-22.60). In multivariate analysis, ER/PR loss independently predicted poor PFS (HR=3.77; 95% CI=1.60-10.14) and OS (HR=5.56; 95% CI=1.37-22.55) for all patients, and poor PFS for patients in stage IA (n=695; HR=5.54; 95% CI=1.28-23.89) and stage II-IV (n=129; HR=5.77; 95% CI=1.57-21.27). No association was found between ER/PR loss and TCGA classification.
Conclusion: Integrating ER/PR evaluation into clinical risk stratification may improve prognosis for grade I-II EEA patients.

KCI등재 SCI SCOPUS

5Peritoneal cancer index in ovarian cancer

저자 : Wonkyo Shin , Sang-yoon Park , Myong Cheol Lim

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-2 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCI SCOPUS

6Tailoring radicality in early cervical cancer: how far can we go?

저자 : Jacobus Van Der Velden , Constantijne H. Mom

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-14 (14 pages)

다운로드

(기관인증 필요)

초록보기

Today, the patient who is diagnosed with early cervical cancer is offered a variety of treatments apart from standard therapy. Patients can be treated with a less radical hysterectomy (RH) regarding parametrectomy, a trachelectomy either vaginal or abdominal, and this can be performed through a minimal invasive or open procedure. All this in combination with nerve sparing and/or sentinel node technique. Level 1 evidence for the oncological safety of all these modifications is only available from 3 randomized controlled trials (RCTs). Two RCTs on more or less radical parametrectomy both showed that oncological safety was not compromised by doing less radical surgery. Because of the heterogeneity of the patient population and the high frequency of adjuvant radiotherapy, the true impact of surgical radicality cannot be assessed. Regarding the issue of oncological safety of fertility sparing treatments, case-control and retrospective case series suggest that trachelectomy is safe as long as the tumor diameter does not exceed 2 cm. Recently, both a RCT and 2 case-control studies showed a survival benefit for open surgery compared to minimally invasive surgery, whereas many previous case-control and retrospective case series on this subject did not show impaired oncological safety. In a case-control study the survival benefit for open surgery was restricted to the group of patients with a tumor diameter more than 2 cm. Although modifications of the traditional open RH seem safe for tumors with a diameter less than 2 cm, ongoing prospective RCTs and observational studies should give the final answer.

KCI등재 SCI SCOPUS

7Current state and outlook for drug repositioning anticipated in the field of ovarian cancer

저자 : Yusuke Kobayashi , Kouji Banno , Haruko Kunitomi , Eiichiro Tominaga , Daisuke Aoki

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-13 (13 pages)

다운로드

(기관인증 필요)

초록보기

Ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer mortality in women. Although standard chemotherapy is the established treatment for ovarian cancer, the prognosis remains poor, and it is highly anticipated that new drugs will be developed. New drugs, such as humanized anti-vascular endothelial growth factor monoclonal antibodies and poly ADP-ribose polymerase inhibitors, are expected to improve clinical outcomes of ovarian cancer. However, long-term, costly research is required to develop such new drugs, and soaring national healthcare costs are becoming a concern worldwide. In this social context, drug repositioning, wherein existing drugs are used to develop drugs with new indications for other diseases, has recently gained attention. Because trials have already confirmed the safety in humans and the pharmacokinetics of such drugs, the development period is shorter than the conventional development of a new drug, thereby reducing costs. This review discusses the available basic experimental and clinical data on drugs used for other types of cancer for which drug repositioning is anticipated to repurpose the drug for the treatment of ovarian cancer. These include statins, which are used to treat dyslipidemia; bisphosphonate, which is used to treat osteoporosis; metformin, which is used to treat diabetes; non-steroidal anti-inflammatory drugs; ivermectin, an antiparasitic agent; and itraconazole, an anti-fungal agent. These drugs will play an important role in future drug repositioning strategies for ovarian cancer. Furthermore, drug repositioning is anticipated to extend not only to ovarian cancer treatment but also to ovarian cancer prevention.

KCI등재 SCI SCOPUS

8Opportunistic salpingectomy in the Netherlands

저자 : Karl Tamussino

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-3 (3 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCI SCOPUS

9Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy

저자 : Ang Qu , Ping Jiang , Haitao Sun , Weijuan Jiang , Yuliang Jiang , Suqing Tian , Junjie Wang

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-11 (11 pages)

다운로드

(기관인증 필요)

초록보기

Objective: To investigate the efficacy of image-guided radioactive 125I seed (IGRIS) implantation for pelvic recurrent cervical cancer (PRCC) after external beam radiotherapy (EBRT), and analyze the influence of clinical and dosimetric factors on efficacy.
Methods: From July 2005 to October 2015, 36 patients with PRCC received IGRIS. We evaluated local progression-free survival (LPFS) and overall survival (OS).
Results: The median follow up was 11.5 months. The 1- and 2-year LPFS rate was 34.9% and 20%, respectively. The multivariate analysis indicated recurrence site (central or pelvic wall) (hazard ratio [HR]=0.294; 95% confidence interval [CI]=0.121-0.718), lesion volume (HR=2.898; 95% CI=1.139-7.372), D90 (HR=0.332; 95% CI=0.130-0.850) were the independent factors affecting LPFS. The 1- and 2-year OS rate was 52.0% and 19.6%, respectively. The multivariate analysis suggested pathological type (HR=9.713; 95% CI=2.136-44.176) and recurrence site (HR=0.358; 95% CI=0.136-0.940) were the independent factors affecting OS. The dosimetric parameters of 33 patients mainly included D90 (128.5±47.4 Gy), D100 (50.4±23.7 Gy) and V100 (86.7%±12.9%). When D90 ≥105 Gy or D100 ≥55 Gy or V100 ≥91%, LPFS was extended significantly, but no significant difference for OS. The 79.2% of 24 patients with local pain were suffering from pain downgraded after radioactive 125I seed implantation.
Conclusion: IGRIS implantation could be a safe and effective salvage treatment for PRCC after EBRT, which could markedly release the pain. Recurrence site, tumor volume and dose were the main factors affected efficacy. Compared with central recurrence, it was more suitable for patients with pelvic wall recurrent cervical cancer after EBRT.

KCI등재 SCI SCOPUS

10Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma

저자 : Yutaka Yoneoka , Hiroshi Yoshida , Mitsuya Ishikawa , Hanako Shimizu , Takashi Uehara , Takashi Murakami , Tomoyasu Kato

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 30권 1호 발행 연도 : 2019 페이지 : pp. 1-12 (12 pages)

다운로드

(기관인증 필요)

초록보기

Objective: Gynecologists occasionally encounter synchronous endometrial and ovarian endometrioid carcinoma (SEO-EC) patients who show favorable prognosis than locally advanced or metastatic disease patients. This study aimed to elucidate prognostic factors of SEO-EC and identify patients who have a sufficiently low risk of recurrence without receiving adjuvant chemotherapy.
Methods: We retrospectively reviewed 46 patients with pathologically confirmed SEO-EC who underwent surgery at the National Cancer Center Hospital between 1997 and 2016. Immunohistochemical evaluation of DNA mismatch repair (MMR) protein expression were performed for both endometrial and ovarian tumors. Patient outcomes were analyzed according to clinicopathologic factors.
Results: From the multivariate analysis, cervical stromal invasion indicated a worse prognosis for progression-free survival (hazard ratio [HR]=6.85; 95% confidence interval [CI]=1.50-31.1) and overall survival (HR=6.95; 95% CI=1.15-41.8). Lymph node metastasis and peritoneal dissemination did not significantly affect survival. MMR deficiency was observed in 13 patients (28.3%), with both endometrial and ovarian tumors showing the same MMR expression status. MMR deficiency was not significantly associated with survival. Of 23 patients with lesions confined to only the uterine body and adnexa, only 2 had recurrence in the group receiving adjuvant therapy, while none of the 10 patients who did not receive adjuvant therapy had recurrence.
Conclusion: SEO-EC patients with tumors localized to the uterine body and adnexa lesions had a low risk for recurrence and may not require adjuvant therapy. SEO-EC may have prognostic factors different from those of endometrial and ovarian cancer.

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

질병관리본부 University of Toronto 목포가톨릭대학교 단국대학교 대검찰청
 8
 3
 2
 1
 1
  • 1 질병관리본부 (8건)
  • 2 University of Toronto (3건)
  • 3 목포가톨릭대학교 (2건)
  • 4 단국대학교 (1건)
  • 5 대검찰청 (1건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기